Sign In
Buy PAVM
$4.68
-0.230 (-4.68%)
At Close: Jun 23, 2026
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
08:00am, Thursday, 13'th Nov 2025
Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor PAVmed signed letter of intent (LOI) to license groundbreaking endoscopi
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
08:00am, Wednesday, 12'th Nov 2025
Processed 2,841 EsoGuard® tests and recognized 3Q25 revenue of $1.2 million, ending quarter with over $47 million in proforma cash and extending runway through 2026 and well past upcoming reimburseme
PAVmed Inc. (NASDAQ:PAVM) Sees Large Growth in Short Interest
01:58am, Monday, 03'rd Nov 2025
PAVmed Inc. (NASDAQ: PAVM - Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 405,600 shares, an increase of 83
PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025
08:01am, Thursday, 30'th Oct 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Oct. 30, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
08:01am, Wednesday, 29'th Oct 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Oct. 29, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention
Head to Head Survey: PAVmed (NASDAQ:PAVM) & Bionik Laboratories (OTCMKTS:BNKL)
02:22am, Tuesday, 21'st Oct 2025
PAVmed (NASDAQ: PAVM - Get Free Report) and Bionik Laboratories (OTCMKTS:BNKL - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
08:01am, Wednesday, 15'th Oct 2025
NEW YORK , Oct. 15, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVm
PAVmed (PAVM) Upgraded to Strong Buy: Here's Why
01:01pm, Friday, 10'th Oct 2025
PAVmed (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
The Veris Cancer Care Platform to be deployed to enhance personalized cancer care in patients undergoing systemic cancer therapy across OSUCCC – James NEW YORK , Oct. 7, 2025 /PRNewswire/ -- PAVmed
Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
08:01am, Tuesday, 16'th Sep 2025
Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage ex
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
09:17am, Thursday, 11'th Sep 2025
NEW YORK , Sept. 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVm
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
08:00am, Wednesday, 10'th Sep 2025
NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PA
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 09'th Sep 2025
NEW YORK , Sept. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAV
Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025
09:16am, Friday, 05'th Sep 2025
Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting NEW YORK , Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc
Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025
08:00am, Wednesday, 27'th Aug 2025
Fireside chat with Chairman & CEO Lishan Aklog, M.D., scheduled for Friday, September 5, at 8:35 AM EDT NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or th
